The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function.

by Christy M Hebner, Bin Han, Katherine M Brendza, Michelle Nash, Maisoun Sulfab, Yang Tian, Magdeleine Hung, Wanchi Fung, Randall W Vivian, James Trenkle, James Taylor, Kyla Bjornson, Steven Bondy, Xiaohong Liu, John Link, Johan Neyts, Roman Sakowicz, Weidong Zhong, Hengli Tang, Uli Schmitz
Published 2012-01-01